CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Lurasidone (Latuda)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02239094
NCT02239094N/ACompleted
CompareCT.gov

Identification of Biosignatures for Lurasidone (Latuda) Response in Bipolar Depression

New York State Psychiatric Institute·interventional·Posted Sep 12, 2014·Updated Dec 12, 2017

In Brief

A clinical study evaluating Lurasidone (Latuda) for Bipolar Depression. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The study proposes to conduct a pilot study of biological predictors of lurasidone response in bipolar depression.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Depression
CountriesUnited States
CollaboratorsSumitomo Pharma America, Inc.

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 12, 2014
Enrollment StartJan 1, 2015
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.8 years ago

Interventions

Lurasidone (Latuda)drug

Antipsychotic medication approved for use with Bipolar disorder